Thrombotic microangiopathy following haematopoietic stem cell transplant

Pediatr Nephrol. 2018 Sep;33(9):1489-1500. doi: 10.1007/s00467-017-3803-4. Epub 2017 Oct 9.

Abstract

Thrombotic microangiopathy is a potentially lethal complication of haematopoietic stem cell (bone marrow) transplantation. The pathophysiology is incompletely understood, although endothelial damage appears to be central. Platelet activation, neutrophil extracellular traps and complement activation appear to play key roles. Diagnosis may be difficult and universally accepted diagnostic criteria are not available. Treatment remains controversial. In some cases, withdrawal of calcineurin inhibitors is adequate. Rituximab and defibrotide also appear to have been used successfully. In severe cases, complement inhibitors such as eculizumab may play a valuable role. Further research is required to define the pathophysiology and determine both robust diagnostic criteria and the optimal treatment.

Keywords: Acute kidney injury; Complement; Hematopoietic stem cell transplant; Neutrophil extracellular traps; Thrombotic microangiopathy.

Publication types

  • Review

MeSH terms

  • ADAMTS13 Protein / blood
  • ADAMTS13 Protein / metabolism
  • Biopsy
  • Calcineurin Inhibitors / administration & dosage
  • Calcineurin Inhibitors / adverse effects
  • Complement Activation / drug effects
  • Complement Activation / immunology
  • Complement Inactivating Agents / therapeutic use
  • Endothelial Cells / immunology
  • Endothelial Cells / pathology
  • Graft vs Host Disease / complications
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / prevention & control
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Incidence
  • Kidney / blood supply
  • Kidney / cytology
  • Kidney / immunology
  • Kidney / pathology*
  • Microvessels / cytology
  • Microvessels / immunology
  • Microvessels / pathology*
  • Plasma Exchange
  • Risk Factors
  • Rituximab / therapeutic use
  • Thrombotic Microangiopathies / diagnosis*
  • Thrombotic Microangiopathies / epidemiology
  • Thrombotic Microangiopathies / etiology
  • Thrombotic Microangiopathies / therapy
  • Treatment Outcome

Substances

  • Calcineurin Inhibitors
  • Complement Inactivating Agents
  • Rituximab
  • ADAMTS13 Protein
  • ADAMTS13 protein, human